drugset
drugset / Trial / NCT01692782

Adult Attention Deficit Hyperactivity Disorder

NCT01692782 ↗

Phase 2 Completed 341 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).

Timeline

Start
2012-12
Primary completion
2013-11
Completion
2013-12

Outcome

Met primary endpoint

registry analysis (superiority or other test); SEP-225289 8mg; p = 0.019; Mean Difference (Final Values) -13.88; Mixed Models Analysis NCT01692782 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 4 mg Oral
Subject Dasotraline Small molecule 8 mg Oral

Indications

attention deficit-hyperactivity disorder